Antimicrobial Resistance Surveillance Market

The global antimicrobial resistance (AMR) surveillance market was valued at $5.9 billion in 2023 and is projected to reach $7.7 billion by 2028, growing at a 5.6% CAGR. Key drivers include the rising prevalence of infections caused by drug-resistant pathogens such as MRSA, VRE, MDR-TB, and CRE. Innovations in diagnostics and government efforts to combat AMR further fuel market growth. Despite these drivers, high costs of diagnostic systems and complex regulatory frameworks present challenges. Emerging economies, especially in Asia-Pacific and Latin America, offer significant growth opportunities. The market includes solutions like diagnostic kits, systems, software, and services, with hospitals and clinics being the primary users. Key players include Luminex, Thermo Fisher Scientific, Cepheid, and Roche Diagnostics. North America dominates the market due to advanced healthcare infrastructure and high AMR prevalence.

Global Antimicrobial Resistance Surveillance Market Trends

To know about the assumptions considered for the study, Request for Free Sample Report

Antimicrobial Resistance Surveillance Market Dynamics

Driver: Growing prevalence of infections caused by drug-resistance pathogens

According to a published article by NCBI, within India, the incidence of VRE infections is on the rise, fluctuating between 1% and 8.7%. Our own investigation further demonstrates an escalating VRE infection rate in the bloodstream, climbing from 6.12% in 2018 to 19.2% in 2020. The growing number of epidemic outbreaks caused by drug-resistance pathogens, such as methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), multi-drug-resistant Mycobacterium tuberculosis (MDR-TB), and carbapenem-resistant Enterobacteriaceae (CRE) gut bacteria is also propelling the demand for antimicrobial resistance surveillance solutions.

Restraint: High cost of antimicrobial resistance diagnostic systems/ kits

Antimicrobial resistance (AMR) exerts a substantial toll on economies. Beyond its human toll of mortality and disability, the protracted illnesses it causes lead to extended hospitalizations, heightened reliance on costlier pharmaceuticals, and financial hardships for affected individuals. Moreover, the pricing of AMR kits and instruments is positioned at a premium level. According to the NorthShore University Health System, the cost of reagents (at a volume of 29,200 tests per year) using automated systems is USD 165,856 per year as opposed to USD 43,508 per year using the disk diffusion method. Furthermore, the use of automated systems results in additional spending of USD 90,668 per year than that required for the semi-automated disk diffusion method.

Academic research laboratories generally cannot afford such systems as they have limited budgets. In addition, the maintenance costs and several other indirect expenses result in an overall increase in the total cost of ownership of these instruments. These factors hinder the mass adoption of antimicrobial resistance surveillance systems.

Opportunity: Growth opportunities in emerging economies

Emerging economies are expected to become a focal point for the growth of the ARS market. The Asia Pacific, Middle Eastern, and Latin American regions are relatively untapped markets for companies as compared to Europe and North America. Russia, India, China, Brazil, and South Africa are significant contributors to antibiotic adoption, accounting for 76% of the increase in antibiotic usage. The changes in antibiotic usage over the last decade have been exceptional, and this is mostly due to the advent of new illnesses. ~USD 3.3 million through the Russian Federation-funded FAO initiative was provided in 2019-20 for assisting national authorities in Armenia, Belarus, Kazakhstan, Kyrgyzstan, and Tajikistan in addressing the dangers presented by antibiotic-resistant microbes in agriculture and food systems.

Challenge: Complex Regulatory Frameworks

Among the major challenges faced by the antimicrobial resistance surveillance market is the time lag between establishing clinical breakpoints, approval of new antimicrobial agents, and the inclusion of these agents in antimicrobial susceptibility testing. Clinical breakpoints are defined as the concentration of an antibiotic that enables the interpretation of AST to define isolates as susceptible, intermediate, or resistant, thereby predicting the efficacy of an antimicrobial drug in treating a clinical disease. The FDA establishes these breakpoints when drug manufacturers submit individual new drug applications or when device manufacturers submit requests to revise the breakpoints.

Antimicrobial Resistance Surveillance Market Ecosystem Map

In 2023, the diagnostic kits segment is projected to account for the largest share of the antimicrobial resistance surveillance industry

By solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the increasing demand for rapid and accurate diagnostics for antimicrobial resistance. Diagnostic kits are used to detect the presence of antimicrobial-resistant bacteria in clinical samples, such as blood, urine, and respiratory secretions.

Clinical Diagnostics is projected to account for the largest share of the antimicrobial resistance surveillance industry in 2023

By application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications . In 2023, the clinical diagnostics segment is expected to command the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as increasing prevalence of antimicrobial resistance, need to improve patient outcomes, used to determine the susceptibility of bacteria to different antimicrobial agents and this information is essential for healthcare providers to make informed decisions about the treatment of patients with antimicrobial-resistant infections.

By end user, hospitals and clinics accounted for the largest share of the antimicrobial resistance surveillance industry

By end users, the global antimicrobial resistance surveillance market has been segmented into hospitals & clinics, research and academic institutes, and others. In 2023, the hospitals & clinics segment is expected to command the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the fact that because they are the primary settings where antimicrobial-resistant infections occur and they are required to conduct antimicrobial resistance surveillance.

By region, North America is projected to account for the largest share of the antimicrobial resistance surveillance industry

By region the global antimicrobial resistance surveillance segmented into—North America, Europe, Asia Pacific, Latin America, and Middle East Africa. In 2023, North American antimicrobial resistance surveillance market is expected to account for the largest share of the global antimicrobial resistance surveillance market. This can be attributed to the presence of leading market players, highest prevalence of antimicrobial resistance, and strong regulatory environment.

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in this market are Luminex Corporation (US), Thermo Fisher Scientific (US), BioSpace (US), Cepheid (US), Accelerate Diagnostics, Inc. (US), Liofilchem S.r.l. (Italy), Becton, Dickinson and Company (US), Biomerieux (France), Bruker (US), Danaher (US), Merck KgaA (Germany), Bio-Rad (US), Qiagen (Germany), Abbott Laboratories (US), Roche Diagnostics (Switzerland), OpGen, Inc. (US), Wolters Kluwer N.V. (US), Lumed (US), Alifax S.r.l. (Italy), and Bioanalyse (Turkey).

Scope of the Antimicrobial Resistance Surveillance Industry:

The study categories the antimicrobial resistance surveillance Market to forecast revenue and analyze trends in each of the following submarkets:

By Solution

• Diagnostic kits
• Diagnostic systems
• Surveillance software
• Services

By Application

• Clinical Diagnostics
• Public Health Surveillance
• Other Applications

By End User

• Hospitals & Clinics
• Research & Academic Institutes
• Others

By Region

• North America
  • US
  • Canada
• Europe
  • France
  • Spain
  • UK
  • Italy
  • Germany
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst